LCS
OCUL icon

Levin Capital Strategies’s Ocular Therapeutix OCUL Stock Holding History

Levin Capital Strategies’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-108,000
Closed -$448K – 261
2022
Q3 		$448K Buy
+108,000
New +$544K 0.06% 122

Other funds holding OCUL

DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
ELI
Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
EOJOAM
E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.21B AUM 82.36% 1-Year Est. Return

Levin Capital Strategies's OCUL Position: Q2 2026 in Review

Levin Capital Strategies opened a new position in Ocular Therapeutix (OCUL) in Q2 2026: 10,000 shares worth $98.2K. The stake represents 0.01% of the portfolio and ranks #254 among its holdings. This is a return to the name: Levin Capital Strategies previously reported a position in OCUL as recently as Q3 2025.

Levin Capital Strategies first reported a position in OCUL in Q4 2019 and has held it in 11 quarters since. The position peaked at $1.09M in Q1 2023. 79 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Levin Capital Strategies held 10,000 shares of Ocular Therapeutix worth $98.2K as of Q2 2026.
  • Ocular Therapeutix was a new Levin Capital Strategies position in Q2 2026.
  • Ocular Therapeutix made up 0.01% of Levin Capital Strategies's portfolio in Q2 2026, its #254 holding.
  • Levin Capital Strategies first reported a position in Ocular Therapeutix in Q4 2019 and has held it in 11 quarters since.
  • Levin Capital Strategies's Ocular Therapeutix position peaked at $1.09M in Q1 2023.
  • 79 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Levin Capital Strategies's 13F filing for Q2 2026, filed 31 Jul 2026.